Detalles de la búsqueda
1.
A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis.
Rheumatology (Oxford)
; 2023 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37471590
2.
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.
J Neurol Neurosurg Psychiatry
; 94(1): 1-9, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36418156
3.
Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.
Mod Rheumatol
; 33(4): 668-679, 2023 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35920102
4.
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years.
Mod Rheumatol
; 33(1): 64-72, 2023 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35365828
5.
Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3).
Mod Rheumatol
; 33(4): 657-667, 2023 Jul 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35921235
6.
Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.
Ann Rheum Dis
; 81(4): 469-479, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34344706
7.
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
Ann Rheum Dis
; 81(2): 184-192, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34740884
8.
Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).
Mod Rheumatol
; 32(1): 59-67, 2022 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33274687
9.
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
Ann Rheum Dis
; 80(7): 848-858, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33504485
10.
Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors.
Rheumatology (Oxford)
; 60(11): 4991-5001, 2021 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33871596
11.
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
Ann Rheum Dis
; 79(10): 1290-1297, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32788396
12.
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Rheumatology (Oxford)
; 59(12): 3834-3844, 2020 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32449924
13.
Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.
Rheumatology (Oxford)
; 59(2): 292-302, 2020 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31312844
14.
Unique Sjögren's syndrome patient subsets defined by molecular features.
Rheumatology (Oxford)
; 59(4): 860-868, 2020 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31497844
15.
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Lancet
; 391(10139): 2513-2524, 2018 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-29908670
16.
Baricitinib in Patients with Refractory Rheumatoid Arthritis.
N Engl J Med
; 374(13): 1243-52, 2016 Mar 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-27028914
17.
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
Ann Rheum Dis
; 78(11): 1454-1462, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31362993
18.
Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study.
Ann Rheum Dis
; 78(2): 171-178, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30194275
19.
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
JAMA
; 322(4): 315-325, 2019 07 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-31334793
20.
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Lancet
; 389(10086): 2317-2327, 2017 06 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28551073